Johnson & Johnson Announces Over $1 Billion Investment for New Cell Therapy Facility in Pennsylvania
Johnson & Johnson has announced an investment exceeding $1 billion for a new cell therapy manufacturing facility. This significant expansion will be situated on a 154-acre property at 1201 Sumneytown Pike in Spring House, Lower Gwynedd, Pennsylvania.
The new facility is strategically designed to expand the company's U.S. manufacturing capacity. It will support Johnson & Johnson's growing portfolio and pipeline of vital medicines for cancer, immune-mediated, and neurological diseases.
Joaquin Duato, Chairman and CEO of Johnson & Johnson, highlighted the broader significance of the investment:
"This investment contributes to the company's legacy in Pennsylvania by integrating scientific excellence, manufacturing capabilities, and community collaboration."
Job Creation and Economic Impact
The project is poised to deliver substantial economic benefits to the region. During the construction phase, approximately 4,000 jobs are expected to be created. Once the facility becomes operational, it is projected to generate 500 skilled biomanufacturing jobs. Johnson & Johnson currently maintains an existing facility in Spring House, which employs 2,500 individuals.
State and Federal Endorsements
Pennsylvania Governor Josh Shapiro praised the investment, emphasizing the state's robust position in life sciences and advanced manufacturing. He attributed the decision to Pennsylvania's economic development plan, diligent efforts to streamline administrative processes, strategic investments in key industries like life sciences, and ongoing workforce development initiatives.
U.S. Senator Dave McCormick underscored Pennsylvania's inherent strengths, including its skilled workforce, premier research institutions, and formidable manufacturing capabilities. Similarly, U.S. Senator John Fetterman and Representative Madeleine Dean recognized the investment's profound potential for job growth, advancement in manufacturing, and its pivotal contribution to healthcare innovation in the region.